RxDoctor Payments Data

Michael Bode, MD

Family Medicine · Brownsburg, INNPI 1689669640

Payments from drug & device makers

$9,251in general payments, 2019–2025

Across 553 payments — averaging $16.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Pfizer$872
  • AstraZeneca$862
  • AbbVie$778
  • Lilly USA, LLC$743
  • GSK$674
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$9,13499%
  • Education$1181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,251 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$107,720
Medicare patients
273
Services billed
2,715

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban144$122,361
JardianceEmpagliflozin83$105,824
OzempicSemaglutide41$58,179
MounjaroTirzepatide45$43,787
RybelsusSemaglutide29$26,728
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr36$21,981
XareltoRivaroxaban22$21,917
Tresiba Flextouch U-100Insulin Degludec12$21,391
FarxigaDapagliflozin Propanediol23$18,496
Spiriva HandihalerTiotropium Bromide26$17,774
EntrestoSacubitril/Valsartan13$13,059
MyrbetriqMirabegron11$9,076
Breo ElliptaFluticasone/Vilanterol24$9,059
Incruse ElliptaUmeclidinium Bromide18$7,660
Fluticasone-SalmeterolFluticasone Propion/Salmeterol53$7,125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$872$128,121157 claims
Boehringer IngelheimJardiance$357$105,82483 claims
Novo NordiskOzempic, Rybelsus$1,422$84,90870 claims
Lilly USA, LLCMounjaro$743$43,78745 claims
GSKAnoro Ellipta, Breo Ellipta, Incruse Ellipta$674$38,70078 claims
AstraZenecaFarxiga, Symbicort$862$21,98036 claims
Johnson & JohnsonXarelto$305$21,91722 claims
NovartisEntresto, Diovan$345$16,27624 claims
Astellas Pharma US IncMyrbetriq$310$9,07611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Brownsburg

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →